Welcome to our dedicated page for PROTO LABS news (Ticker: $PRLB), a resource for investors and traders seeking the latest updates and insights on PROTO LABS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PROTO LABS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PROTO LABS's position in the market.
Protolabs, Inc. reported strong financial results for Q1 2024 with a total revenue of $128 million, up 1.6% YoY. The revenue from Protolabs Network saw a significant increase of 39% YoY to $24 million. GAAP earnings per share were $0.20, while non-GAAP earnings per share stood at $0.40. The company remains focused on driving profitable growth and enhancing shareholder value.
Protolabs (NYSE: PRLB) collaborates with BioDapt to create custom prosthetics for elite athletes, including Paralympians, through its innovative digital manufacturing services. Founder Mike Schultz, a Paralympic Gold Medalist, leads BioDapt in designing high-performance prosthetic equipment. Protolabs' quick-turn manufacturing capabilities have been important in supporting BioDapt's mission to provide elite adaptive athletes with custom parts that enhance their athletic performance. The partnership has allowed athletes like Noelle Lambert to pursue their Paralympic dreams with cutting-edge prosthetic solutions.
